A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.

Source:http://linkedlifedata.com/resource/pubmed/id/17252015

Download in:

View as

General Info

PMID
17252015